Sign In
Get Clay Free →

Suggestions

    Mary Seideman

    Head of Clinical Affairs

    Professional Background

    Dr. Mary Seideman is a distinguished physician-scientist and healthcare executive renowned for her unique blend of medical, scientific, and business acumen. Currently serving as the Head of Clinical Affairs at W2O Group, a pioneering healthcare consultancy, she is deeply invested in developing data-driven and technology-enhanced Medical Affairs solutions. Dr. Seideman's work focuses on identifying and leveraging emerging trends in healthcare professional (HCP) behaviors, especially those observed on social media platforms, to shape effective medical launch strategies that optimize commercial success. Her analytical approach and strategic foresight have positioned her as a leader in evolving healthcare landscapes.

    Before taking on her current leadership role, Dr. Seideman built an impressive career trajectory with significant contributions to North American and Global Medical Affairs. Her extensive experience encompasses clinical development, diagnostics leadership, and strategic launch planning at world-class pharmaceutical organizations such as Genentech, Cephalon, and GlaxoSmithKline (GSK). In these roles, she skillfully orchestrated the launch planning for several pharmacological compounds by overseeing critical activities including Investigator-Sponsored Trials (IST) planning and execution, KOL (Key Opinion Leader) engagement, advisory board strategies, Medical Science Liaison (MSL) training, as well as commercial and clinical development partnerships.

    Dr. Seideman's entrepreneurial spirit shone through in 2012 when she co-founded Arcus Medica, a boutique medical communications and consulting firm. At Arcus Medica, she provided strategic counsel on product launches spanning various medical areas, including oncology, hematology, neurology, autoimmune disorders, and rare diseases. Her insightful guidance aided clients ranging from small biotech firms to major pharmaceutical companies, covering all phases of the product lifecycle. Notably, she developed the Arcus Medica KOL Advisory Board, an innovative engagement network of hundreds of translational, clinical, scientific, academic, and community experts. This collaborative network was instrumental in providing invaluable feedback on strategic initiatives, tactical approaches, and the execution of medical strategies.

    Education and Achievements

    Dr. Seideman's foundational education is rooted in her early curiosity about medical science. She initiated her medical-scientific career while still in high school at the prestigious Memorial Sloan Kettering Cancer Center, where she investigated the causes of thrombocytopenia in patients undergoing experimental immunotherapy for neuroblastoma. Dr. Seideman pursued a Bachelor of Arts degree in Molecular Biology at Princeton University, where she conducted her thesis research under the esteemed guidance of Dr. Arnold J. Levine. Her thesis centered around characterizing the expression of the pivotal p53 tumor suppressor gene in mdm2 knockout mice, underscoring her commitment to advancing cancer research.

    Demonstrating unyielding dedication to advancing her expertise, Dr. Seideman earned her M.D.-Ph.D. from New York University School of Medicine, focusing her research on immune suppressor cells. Following her dual degree accomplishment, she underwent rigorous pediatrics training at the Boston Combined Residency Program, a collaboration between Harvard Medical School and Boston Medical Center. She further specialized in hematology-oncology at Memorial Sloan Kettering Cancer Center and Cornell University, where her research tackled cancer vaccine development and characterized immune responses in patients post-bone marrow transplant.

    Achievements

    Dr. Seideman's contributions to the field of medicine and healthcare extend beyond her individual work. As an Editorial Board member of Physician Women SOAR, a nationwide initiative focused on antiracism within the physician community, she actively promotes diversity and equity in healthcare. Her role in this organization exemplifies her commitment to fostering an inclusive environment for all healthcare professionals.

    Throughout her career, Dr. Seideman's leadership skills and expert knowledge have enabled her to make significant strides in the medical community. She is widely recognized for her strategic vision and practical approach to medicine, especially in the fast-paced sectors of oncology and hematology. Her ability to integrate scientific research, clinical knowledge, and commercial strategies has empowered healthcare companies to achieve impactful results and ultimately improve patient care.

    Dr. Mary Seideman's journey illustrates a remarkable blend of scientific inquiry, clinical excellence, and business leadership. As the healthcare landscape continues to evolve, her expertise remains vital in paving the way for innovative medical strategies that align with future healthcare priorities.

    Related Questions

    How did Dr. Mary Seideman develop her expertise in Medical Affairs and clinical strategy?
    What are the key trends in HCP behaviors that Dr. Mary Seideman focuses on in her role at W2O Group?
    Can Dr. Mary Seideman share insights on the impact of social media on healthcare professional engagement?
    What motivated Dr. Mary Seideman to co-found Arcus Medica, and what was her vision for the company?
    How has Dr. Mary Seideman's educational background influenced her career in medicine and healthcare leadership?
    What challenges has Dr. Mary Seideman faced in her roles at major pharmaceutical companies and how has she overcome them?
    M
    Add to my network

    Location

    Philadelphia, Pennsylvania